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INTRODUCTION 
Acute bronchiolitis is the most common cause of lower 
respiratory tract infection and the most common cause of 
hospitalization due to respiratory illness during infancy. 
About 50,000 to 80,000 per year hospitalizations occur in 
children under one years old groups in the United States 
are attributed to the acute bronchiolitis.1 According to 
western statistics, 11.4 cases per 100 children under one 
years old and six per 100 children at 1-2 years old get 
bronchiolitis.2 Acute bronchiolitis which most children are 
sensitive to is associated with symptoms such as fever, 
wheezing and cough. Most of the cause is respiratory 
syncytial virus (RSV) but mycoplasma and other viruses 
can also be risk factors. Acute bronchiolitis is often 
associated pathologically with bronchiectasis and in this 
fibroblasts and collagen do not appear in the biopsy and 
diseases often improve spontaneously.3 The clinical signs 
of acute bronchiolitis are like viral pneumonia and the 
most important symptoms are fever and wheezing and 
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increase breathing rate.4 In infants especially infants under 
six months, due to the small diameter of the airways, 
edema and inflammation of the bronchioles can lead to 
respiratory distress.1 Therefore appropriate treatment is 
needed. Treatment is often supportive and includes fluid 
therapy, antipyretic drugs and oxygen.5 Recently more 
studies have been done about treatments for bronchial 
dilators such as salbutamol and epinephrine as 
nebulizers.4,5 There is no consensus on the use of 
bronchodilators and beta agonists.6,7 Inhaled salbutamol 
(ventolin) is currently used in Iranian hospitals to treat 
patients with bronchiolitis but several studies have shown 
that it is not effective.8 Need for zinc minerals in burns, 
liver cirrhosis, diabetes, gastrectomy anorexia, genetic 
disorders, premature infants, chronic infections, bowel 
diseases, pancreatic diseases, kidney disease, skin 
disorders, stress and trauma may increase. Zinc is essential 
for maintaining the structure of nucleic acids, proteins and 
cell membranes. In addition, normal growth and cell 
division, tissue repair, sexual maturation and reproductive 
system, wound healing, immune defense and possibly the 
dynamics of physiological zinc dependent actions.9,10 
Studies show a positive effect of zinc on the improvement 
of pneumonia.10,11 There is no consensus on the positive 
effect of zinc sulfate on the recovery of bronchiolitis. The 
aim of this study was to compare the effect of Zinc 
gluconate and placebo in the treatment of tachypnea, 
dyspnea and fever in children aged 2 to 23 months with 
acute bronchiolitis. 
METHODS 
This clinical trial study was performed on 100 children 
aged 2 to 23 months who referred to emergency 
Department of Ardabil Pediatric Hospital with diagnosis 
of acute viral bronchiolitis at 2018. Children aged 2 to 23 
months; first episode of wheezing following viral upper 
airway infection and clinical manifestations of acute 
bronchiolitis including wheezing, rhinorrhea, tachypnea 
(RR> 50/min at rest in infant under one year and RR 
>40/min at rest in infants over one year), cyanosis, 
subcostal and intercostal retraction, nasal flaring and fever 
(axillary temperature above 37.3 °C and oral temperature 
above 37.8 °C and rectal temperature above 38.3 °C) with 
or no apnea episodes and no consolidation in CXR were 
included in the study and children with a history of 
previous wheezing episodes, a history of asthma and 
allergies in their family, recent antibiotic use, chronic heart 
and lung disease, immunodeficiency, down syndrome, 
metabolic or neurological diseases, history of prematurity 
or the use of mechanical ventilation in neonates, zinc 
intake during the last month, severe malnutrition and 
eventually critically ill children who needed immediate 
hospitalization due to dehydration and decreased 
consciousness and lethargy or with respiratory failure 
symptoms were excluded from the study.  
The children were randomly divided into two groups of 50 
each. One group received 1% zinc gluconate orally (1 
cc/kg in infants under 1 year of age and 10 cc (20 mg) in 
infants over one year of age) and the other group received 
placebo (sucrose 30 g, oral flavoring, dextrose serum 5% 
to 100%). Zinc gluconate and placebo syrups were similar 
in appearance and taste, smell and color. The study design 
was single blind and patients were not aware of the type of 
drug being administered. In this study, infants in both 
treatment and placebo groups in toward clinical 
manifestations including tachypnea, subcostal and 
intercostal retraction, wheezing, cyanosis, fever, 
rhinorrhea and nasal flaring at zero, 24, 72 hours and 7 
days after starting the drug followed and researcher 
completed the relevant checklists. After completing the 
checklists for all patients, descriptive statistical methods 
were used to analyze data. chi-square and t-test were used 
for statistical analysis in SPSS version 19 and p value less 
than 0.05 was considered significant. The written consent 
form was completed for all samples and the study 
approved by the Ethics Committee of Ardabil university of 
medical sciences by code IR.ARUMS.REC.1397.097. 
Also, the study was registered with IRCT201603-
18027097N12 at the Clinical Trial Registration Center of 
Iran.  
RESULTS 
Of all samples, 59% were male and 41% were female. The 
sex distribution of the treatment group was 31 males (62%) 
and 19 females (38%) and the placebo group was 28 males 
(56%) and 22 females (44%). The average age of the 
patients was 5.88±4.27 months (2-21 months) and the 
treatment group was 5.82±4.13 and the placebo group was 
5.94±4.46. There was no significant difference between 
the two groups in terms of age and gender. Patients in the 
two treatment and control groups at baseline included 
clinical symptoms including wheezing (p=0.1), fever 
(p=0.305), rhinorrhea (p=0.313), tachypnea (p=0.556), 
nasal flaring (p=0.779), sub rib retraction (p=0.423), inter 
rib retraction (p=0.423), and cyanosis (p=0.505) were not 
statistically significant (Table 1). 
Patients in the two treatment and control groups did not 
show any statistically significant difference in clinical 
symptoms at 24 hours after treatment but at 72 hours after 
treatment, the difference between the two groups was 
statistically significant in terms of the number of people 
with wheezing (p=0.023) and rhinorrhea (p=0.027) and the 
frequency of wheezing (16% vs. 36%) and rhinorrhea 
(zero vs. 12%) were significantly lower in the zinc treated 
group than in the placebo group. On the 7th day after 
treatment, the clinical symptoms of all patients in two 
groups were eliminated (Table 2). 
Frequency of complete recovery at 24 hours in treatment 
group was 8% and 2% in placebo group (p=0.362) and 
frequency of complete recovery at 72 hours in treatment 
group was 74% and in placebo group was 46% (p=0.004). 
By the seventh day after treatment all patients in both 
groups had been recovered. The average length of stay in 
the treatment group was 4.04±1.21 days and in the placebo 
group was 4.64±1.23 days the difference between the two 
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groups was statistically significant (p=0.016) and length of 
stay among patients in the treatment group were 
significantly shorter than patients in the placebo group 
(Table 3). 
Table 1: Clinical symptoms in patients in two groups. 
Groups variables  
Treatment  
(n=50) 
Placebo  
(n=50)  P value  
N % N % 
Whizzing  
+ 50 100 50 100 
1 
- 0 0 0 0 
Fever  
+ 22 44 17 34 
0.3 
- 28 56 33 66 
Rhinorrhea  
+ 26 52 31 62 
0.3 
- 24 48 19 38 
Tachypnea  
+ 42 84 44 88 
0.56 
- 8 16 6 12 
Nasal flaring 
+ 7 14 8 16 
0.78 
- 43 86 42 84 
Sub-gear 
retraction 
+ 24 48 28 56 
0.42 
- 26 52 22 44 
Inter-gear 
retraction 
+ 26 52 21 42 
0.42 
- 24 48 29 58 
Cyanosis 
+ 6 12 4 8 
0.51 
- 44 88 46 92 
Table 2: Clinical symptoms in patients in two groups by times. 
Times  
Variables  
24 hours later 72 hours later  7 days later 
Treatment Placebo 
P value 
Treatment Placebo 
P value 
Treatment Placebo 
N % N % N % N % N % N % 
Whizzing  
+ 38 76 43 86 
 0.2  
8 16 18 36 
0.02 
0 0 0 0 
- 12 24 7 14 42 84 32 64 50 100 50 100 
Fever  
+ 4 8 8 16 
0.21 
1 2 2 4 
1 
0 0 0 0 
- 46 92 42 84 49 98 48 96 50 100 50 100 
Rhinorrhea  
+ 13 26 17 34 
0.38 
0 0 6 12 
0.03 
0 0 0 0 
- 37 74 33 66 50 100 44 88 50 100 50 100 
Tachypnea  
+ 20 40 24 48 
0.42 
4 8 6 12 
0.5 
0 0 0 0 
- 30 60 26 52 46 92 44 88 50 100 50 100 
Nasal 
Flaring 
+ 1 2 3 6 
0.62 
0 0 0 0 
1 
0 0 0 0 
- 49 98 47 94 50 100 50 100 50 100 50 100 
Sub-gear 
retraction 
+ 7 14 11 22 
0.3 
0 0 3 6 
0.2 
0 0 0 0 
- 43 86 39 78 50 100 47 94 50 100 50 100 
Inter-gear 
retraction 
+ 4 8 9 18 
0.14 
0 0 2 4 
0.5 
0 0 0 0 
- 46 92 41 82 50 100 48 96 50 100 50 100 
Cyanosis 
+ 2 4 1 2 
1 
1 2 0 0 
1 
0 0 0 0 
- 48 96 49 98 49 98 50 100 50 100 50 100 
Table 3: The frequency of completed recovery in patients in two groups. 
Groups times  
Treatment 
(n=50) 
Placebo 
(n=50) P value  
N % N % 
24 hours 
Yes 4 8 1 2 
0.36 
No 46 92 49 98 
72 hours 
Yes 37 74 23 46 
0.004 
No 13 26 27 54 
In 7th day 
Yes 50 100 50 100 
1 
No 0 0 0 0 
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DISCUSSION 
The findings of the present study showed that in generally 
the process of healing of bronchiolitis in the treated infants 
with zinc was more favorable than the placebo group; this 
positive effect on wheezing and rhinorrhea was 
statistically significant at 72 hours after treatment. In 
addition, the majority of patients in the treatment group 
recovered from the disease within 72 hours of treatment 
(74% vs. 46%, p=0.004) and the average length of stay in 
the treatment group was significantly lower than the 
placebo group (4.4±1.21 versus 4.64±1.23 days and 
p=0.016). A study by Mahyar et al in Qazvin at 2017 which 
investigated the effect of zinc sulfate in the treatment of 
acute bronchiolitis in children showed that the process of 
clinical symptoms improvement in the zinc sulfate group 
compared to the placebo group was more favorable at 24, 
48, 72, 96 and 120 hours after treatment, which was 
consistent with the findings of the present study.12 Also, 
the improvement of wheezing at 48 and 72 hours and 
complete recovery within 72 hours after treatment was 
significantly greater in the zinc sulfate group and length of 
stay in hospital significantly longer than the placebo group 
which was similar to our study results. But in another study 
conducted by Heydarian et al in Mashhad, different 
findings were reported from our study. In their study zinc 
sulfate had no profit in improving clinical presentation or 
complete recovery or length of hospitalization. We could 
say that the design of our study and both of the above 
studies were a randomized placebo controlled clinical trial 
and all three infants were studied 2 to 23 months. 
However, the difference between our study and that of 
Heydarian et al was in the number of patients studied (100 
patients versus 50 patients) this small sample size in their 
study, along with other factors such as intrinsic differences 
in the study participants, differences in disease 
characteristics such as differences in disease severity, 
differences in disease definition or differences in 
definition of recovery, can all result in different results two 
studies have been effective.9 Studies investigating the 
effect of pediatric pneumonia have also been divided into 
two groups with some concurring with our finding that 
zink supplementation has a beneficial effect on the 
treatment of pneumonia but some link between zinc 
supplementation and pneumonia treatment have not been 
demonstrated. For example a study by Yuan et al in China 
showed that zinc deficiency is common in infants with 
severe pneumonia, but supplemental zinc normalization 
did not improve the clinical outcome of infants with 
pneumonia.13 A study by Fataki et al in Tanzania showed 
no evidence of beneficial effects of zinc in the treatment of 
children with acute pneumonia.14 In a study by Brant et al 
in Nepal zinc auxiliary treatment did not accelerate the 
recovery time of children with severe or non-severe 
pneumonia.15 A study by Boze et al in India showed that 
zinc supplementation had no significant effect on length of 
stay or symptoms of severe pneumonia in children.16 In a 
study in India at 2017 by Nayir et al, they investigated the 
effect of zinc in the treatment of acute respiratory 
infections in children aged 2 to 60 months and their study 
provided a significant advantage for zinc supplementation 
during the episode of acute respiratory infections did not 
show a decrease in the duration or complications of the 
disease.17 But contrary to above studies and consistent with 
our findings a 2004 study by Brooks et al in Bangladesh 
showed that zinc supplementation in infants with severe 
pneumonia had a significant effect on decreasing the 
duration of breast compression, Tachypnea, has hypoxia 
thereby significantly reducing the duration of illness and 
length of stay.10 A study by Valavi et al in Ahwaz in 2012 
showed that the duration of fever and respiratory distress 
were significantly shorter in infants treated with zinc 
compared to placebo and patients required significantly 
shorter hospitalizations than controls.18 A study by Besnet 
et al in India also found that zinc supplementation reduces 
the time of severe pneumonia and the risk of treatment 
failure in children but the decrease in their study was not 
statistically significant.19 Other studies have also shown a 
positive effect of zinc on pneumonia in that it prevents 
pneumonia.20-22 
The advantage of zinc in our study increased 72 hours after 
consumption; this delay in start of impact has also been 
reported in other studies and it may be essential in the 
mechanism of the zinc effect; for example in the Broks et 
al study advantage was increased over 100 hours after use 
and in the Mahyar et al study after 72 hours.10,12 In the 
present study due to the lack of resources and credentials 
we unable to measure the serum level of patients at 
baseline and at release time because by this we could also 
examine the effectiveness of zinc supplementation by 
separating zinc deficient groups with suitable zinc levels. 
A number of studies have shown that irrespective of the 
status zinc in the child, zinc can enhance the acute phase 
response and the protective immune response in which 
case even children with enough zinc intake may also 
benefit from zinc supplementation benefit from illness 
time.10 In the present study no significant effects of zinc 
supplementation were observed in the treatment group. 
Most of the previous studies have not reported a significant 
complication and only a few studies have reported 
vomiting after zinc supplementation in some 
patients.14,15,19 Overall zinc supplements appear to be well 
tolerated and safe by infants. Like most studies this study 
had limitations including: lack of previous studies for 
comparison of the results of the present study with other 
studies. Unable to measure serum zinc levels at the time of 
study entry and discharge time due to a lack of resources.  
CONCLUSION  
The findings of the present study showed that zinc 
gluconate supplementation was effective in accelerating 
the improvement of clinical symptoms in infants aged 2 to 
23 months with acute bronchiolitis and it reduces the 
length of hospital stay which was greater in the first 72 
hours. Because of limited studies in this area, further 
research is needed to provide appropriate 
recommendations for the use of zinc in the treatment of 
bronchiolitis in other population. 
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